Millar Kerri-Ann's Form 4 filing
Cue Biopharma, Inc. (CUE) · filed Oct 5, 2021
- Accession no.
- 0001209191-21-059698
- Filed
- Oct 5, 2021
- Trade date
- Aug 23-Oct 1, 2021
- Filing delay
- 43 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $17.8K. It was filed 43 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Millar Kerri-AnnCIK 0001739126 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2021 | Common Stock | MOption exerciseAcquired | +6,667 | $0.00 | $0 | 12,433 | Direct | |
| Aug 23, 2021 | Common Stock | FTax withholdingDisposed | −1,961 | $0.00 | $0 | 10,472 | Direct | |
| Oct 1, 2021 | Common Stock | MOption exerciseAcquired | +1,251 | $7.50 | +$9,382.5 | 11,723 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −1,251 | $14.21 | −$17,776.71 | 10,472 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2021 | Common Stock | MOption exerciseDisposed | −6,667 | $0.00 | $0 | 6,667 | Direct | |
| Oct 1, 2021 | Common Stock | MOption exerciseDisposed | −1,251 | $0.00 | $0 | 53,749 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.